Sumitomo Chemical India Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Sumitomo Chemical India Limited (NSE:SUMICHEM) just released its quarterly report and things are looking bullish. Sumitomo Chemical India delivered a significant beat to revenue and earnings per share (EPS) expectations, hitting ₹11b-13% above indicated-and₹3.57-23% above forecasts- respectively This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Sumitomo Chemical India after the latest results.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

After the latest results, the six analysts covering Sumitomo Chemical India are now predicting revenues of ₹36.0b in 2026. If met, this would reflect a reasonable 7.0% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to expand 13% to ₹12.65. Before this earnings report, the analysts had been forecasting revenues of ₹36.2b and earnings per share (EPS) of ₹12.16 in 2026. The analysts seems to have become more bullish on the business, judging by their new earnings per share estimates.

View our latest analysis for Sumitomo Chemical India

The analysts have been lifting their price targets on the back of the earnings upgrade, with the consensus price target rising 5.2% to ₹619. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. There are some variant perceptions on Sumitomo Chemical India, with the most bullish analyst valuing it at ₹690 and the most bearish at ₹545 per share. The narrow spread of estimates could suggest that the business' future is relatively easy to value, or thatthe analysts have a strong view on its prospects.

Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. The analysts are definitely expecting Sumitomo Chemical India's growth to accelerate, with the forecast 9.4% annualised growth to the end of 2026 ranking favourably alongside historical growth of 4.0% per annum over the past five years. Compare this with other companies in the same industry, which are forecast to see revenue growth of 13% annually. So it's clear that despite the acceleration in growth, Sumitomo Chemical India is expected to grow meaningfully slower than the industry average.

The Bottom Line

The most important thing here is that the analysts upgraded their earnings per share estimates, suggesting that there has been a clear increase in optimism towards Sumitomo Chemical India following these results. On the plus side, there were no major changes to revenue estimates; although forecasts imply they will perform worse than the wider industry. We note an upgrade to the price target, suggesting that the analysts believes the intrinsic value of the business is likely to improve over time.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. At Simply Wall St, we have a full range of analyst estimates for Sumitomo Chemical India going out to 2028, and you can see them free on our platform here..

We also provide an overview of the Sumitomo Chemical India Board and CEO remuneration and length of tenure at the company, and whether insiders have been buying the stock, here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.